Practical Osteoporosis Management: Topical Review

1. Anderson JJ Woelffer KE Holtzman JJ Jacobs AM : Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg. 43:285–289, 2004. S1067251604004193 [pii] https://dx-doi-org.web.bisu.edu.cn/10.1053/j.jfas.2004.07.005

2. Armas LA Hollis BW Heaney RP : Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 89:5387–5391, 2004. 89/11/5387 [pii] https://dx-doi-org.web.bisu.edu.cn/10.1210/jc.2004-0360

3. Arum SM : New developments surrounding the safety of bisphosphonates. Curr Opin Endocrinol Diabetes Obes. 15:508–513, 2008. 10.1097/MED.0b013e3283184017 01266029-200812000-00006 [pii]

4. Barrett-Connor E Mosca L Collins P : Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 355:125–137, 2006. 355/2/125 [pii] https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa062462

5. Bischoff-Ferrari HA Giovannucci E Willett WC : Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 84:18–28, 2006. 84/1/18 [pii]

6. Canalis E Giustina A Bilezikian JP : Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 357:905–916, 2007. 357/9/905 [pii] https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMra067395

7. Chesnut CH 3rd. Silverman S Andriano K : A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 109:267–276, 2000. S0002934300004903 [pii]

8. Delmas PD Marin F Marcus R : Beyond hip: importance of other nonspinal fractures. Am J Med. 120:381–387, 2007. S0002-9343(06)00672-3 [pii] https://dx-doi-org.web.bisu.edu.cn/10.1016/j.amjmed.2006.06.003

9. El Maghraoui A Roux C : DXA scanning in clinical practice. QJM. 101:605–617, 2008. hcn022 [pii] https://dx-doi-org.web.bisu.edu.cn/10.1093/qjmed/hcn022

10. Finkelstein JS Hayes A Hunzelman JL : The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 349:1216–1226, 2003. 1 https://dx-doi-org.web.bisu.edu.cn/0.1056/NEJMoa035725NEJMoa035725[pii]

11. Garnero P Hausherr E Chapuy MC : Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 11:1531–1538, 1996.

12. Gehrig L Lane J O'Connor MI : Osteoporosis: management and treatment strategies for orthopaedic surgeons. J Bone Joint Surg Am. 90:1362–1374, 2008. 90/6/1362 [pii]

13. Gennari C : Analgesic effect of calcitonin in osteoporosis. Bone. 30:67S–70S, 2002. S8756328202007135 [pii]

14. Gough A Abraha H Li F : Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med. 14:527–531, 1997.https://dx-doi-org.web.bisu.edu.cn/10.1002/(SICI)1096-9136(199707)14:7<527::AID-DIA404>3.0.CO;2-Q

15. Haczynski J Jakimiuk A : Vertebral fractures: a hidden problem of osteoporosis. Med Sci Monit. 7:1108–1117, 2001. 1911 [pii]

16. Hasselman CT Vogt MT Stone KL : Foot and ankle fractures in elderly white women. Incidence and risk factors. J Bone Joint Surg Am. 85-A:820–824, 2003.

17. Heaney RP Davies KM Chen TC : Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 77:204–210, 2003.

18. Hollis BW : Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 135:317–322, 2005. 135/2/317 [pii]

19. Jude EB Selby PL Burgess J : Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. 44:2032–2037, 2001.https://dx-doi-org.web.bisu.edu.cn/10.1007/s001250100008

20. Kamel HK : Postmenopausal osteoporosis: etiology, current diagnostic strategies, and nonprescription interventions. J Manag Care Pharm. 12:S4–9; quiz S26–28, 2006. 2006(12)6:4–9 [pii]

21. Kates SL Kates OS Mendelson DA : Advances in the medical management of osteoporosis. Injury. 38 Suppl 3:S17–23, 2007. S0020-1383(07)00318-X [pii] https://dx-doi-org.web.bisu.edu.cn/10.1016/j.injury.2007.08.007

22. Kurland ES Heller SL Diamond B : The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1–34)]. Osteoporos Int. 15:992–997, 2004. 10.1007/s00198-004-1636-z

23. Lane JM Nydick M : Osteoporosis: current modes of prevention and treatment. J Am Acad Orthop Surg. 7:19–31, 1999.

24. Lane NE : Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 194:S3–11, 2006. S0002-9378(05)01370-0 [pii] https://dx-doi-org.web.bisu.edu.cn/10.1016/j.ajog.2005.08.047

25. Lane NE Kelman A : A review of anabolic therapies for osteoporosis. Arthritis Res Ther. 5:214–222, 2003. 10.1186/ar797

26. Lewiecki EM : Prevention and treatment of postmenopausal osteoporosis. Obstet Gynecol Clin North Am. 35:301–315, ix, 2008. S0889-8545(08)00024-7 [pii] 10.1016/j.ogc.2008.03.007

27. Lindsay R Scheele WH Neer R : Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 164:2024–2030, 2004. 164/18/2024 [pii] https://dx-doi-org.web.bisu.edu.cn/10.1001/archinte.164.18.2024

28. McClung MR San Martin J Miller PD : Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 165:1762–1768, 2005. 165/15/1762 [pii] 10.1001/archinte.165.15.1762

29. McCormick RK : Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility. Altern Med Rev. 12:113–145, 2007.

30. Munoz-Torres M Alonso G Raya MP : Calcitonin therapy in osteoporosis. Treat Endocrinol. 3:117–132, 2004.

31. Neer RM Arnaud CD Zanchetta JR : Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344:1434–1441, 2001. MJBA-441904 [pii]

32. Orwoll ES Scheele WH Paul S : The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 18:9–17, 2003.

33. Pitocco D Ruotolo V Caputo S : Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care. 28:1214–1215, 2005. 28/5/1214 [pii]

34. Rossouw JE Anderson GL Prentice RL : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 288:321–333, 2002. joc21036 [pii]

35. Shea B Wells G Cranney A : Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev. CD004526, 2004. https://dx-doi-org.web.bisu.edu.cn/10.1002/14651858.CD004526.pub2

36. Stroup J Kane MP Abu-Baker AM : Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 65:532–539, 2008. 65/6/532 [pii] https://dx-doi-org.web.bisu.edu.cn/10.2146/ajhp070171

37. US Department of Health and Human Services, Office of the Surgeon General. Bone health and osteoporosis: a report of the surgeon general. Rockville (MD). 2004.